Cargando…
A phase II study of the PI3K inhibitor copanlisib in combination with the anti-CD20 monoclonal antibody rituximab for patients with marginal zone lymphoma: treatment rationale and protocol design of the COUP-1 trial
BACKGROUND: Advanced stage marginal zone lymphoma (MZL) is an incurable indolent B-cell lymphoma, for which a wide variety of treatments ranging from single agent rituximab to more dose intense immunochemotherapy exists. One of the major goals in this palliative setting is to develop chemotherapy-fr...
Autores principales: | Grunenberg, Alexander, Kaiser, Lisa M., Woelfle, Stephanie, Schmelzle, Birgit, Viardot, Andreas, Möller, Peter, Barth, Thomas F. E., Muche, Rainer, Dreyhaupt, Jens, Raderer, Markus, Kiesewetter, Barbara, Buske, Christian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8243426/ https://www.ncbi.nlm.nih.gov/pubmed/34187401 http://dx.doi.org/10.1186/s12885-021-08464-6 |
Ejemplares similares
-
Copanlisib plus rituximab combination therapy vs. rituximab monotherapy for relapsed indolent non-Hodgkin lymphoma: a cost-effectiveness analysis
por: Tang, Xiao, et al.
Publicado: (2022) -
Copanlisib population pharmacokinetics from phase I–III studies and exposure–response relationships in combination with rituximab
por: Morcos, Peter N., et al.
Publicado: (2023) -
Clinical relevance of molecular aspects in extranodal marginal zone lymphoma: a critical appraisal
por: Raderer, Markus, et al.
Publicado: (2023) -
Update on the role of copanlisib in hematologic malignancies
por: Le, Thuy, et al.
Publicado: (2021) -
Feasibility of Combining the Phosphatidylinositol 3-Kinase Inhibitor Copanlisib With Rituximab-Based Immunochemotherapy in Patients With Relapsed Indolent B-cell Lymphoma
por: Matasar, Matthew J., et al.
Publicado: (2021)